Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Exclusion Criteria

• •Current use of obeticholic acid (OCA)
• •New initiation GLP-1 agonists such as liraglutide, exenatide , lixisenatide, albiglutide or dulaglutide within 3 months of screening
• •Pregnant or nursing (lactating) women
• •Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 5 days after stopping study medication
• •Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening
• •Clinical evidence of hepatic decompensation or severe liver impairment
• •Previous diagnosis of other forms of chronic liver disease
• •Uncontrolled diabetes mellitus
• •History or current diagnosis of ECG abnormalities
• •Patients with contraindications to MRI imaging